VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q42754514 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241221010715.0
008 241221nneanz||abbn n and d
035 ‎‡a (WKP)Q42754514‏
024 ‎‡a 0000-0001-5023-310X‏ ‎‡2 orcid‏
035 ‎‡a (OCoLC)Q42754514‏
100 0 ‎‡a Wen-hsing Lin‏ ‎‡9 sl‏
400 0 ‎‡a Wen-hsing Lin‏ ‎‡c researcher‏ ‎‡9 en‏
400 0 ‎‡a Wen-hsing Lin‏ ‎‡c wetenschapper‏ ‎‡9 nl‏
400 0 ‎‡a Wen-hsing Lin‏ ‎‡c investigador/a‏ ‎‡9 es‏
400 0 ‎‡a Wen-hsing Lin‏ ‎‡c investigador‏ ‎‡9 ast‏
670 ‎‡a Author's 3-Phenyl-1H-5-pyrazolylamine-based derivatives as potent and efficacious inhibitors of FMS-like tyrosine kinase-3‏
670 ‎‡a Author's 3-Phenyl-1H-5-pyrazolylamine-based derivatives as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).‏
670 ‎‡a Author's 3D-QSAR-assisted drug design: identification of a potent quinazoline-based Aurora kinase inhibitor.‏
670 ‎‡a Author's A cell-based high-throughput screen for epidermal growth factor receptor pathway inhibitors‏
670 ‎‡a Author's A novel aurora-A inhibitor, BPR1K0609S1, sensitizes colorectal tumor cells to 5-fluorofracil (5-FU) treatment‏
670 ‎‡a Author's Antiviral drug discovery against SARS-CoV.‏
670 ‎‡a Author's Association study of genetic polymorphisms of SLC2A10 gene and type 2 diabetes in the Taiwanese population.‏
670 ‎‡a Author's Aurora kinase A inhibitors: identification, SAR exploration and molecular modeling of 6,7-dihydro-4H-pyrazolo-[1,5-a]pyrrolo[3,4-d]pyrimidine-5,8-dione scaffold‏
670 ‎‡a Author's Aurora kinase inhibitors reveal mechanisms of HURP in nucleation of centrosomal and kinetochore microtubules‏
670 ‎‡a Author's BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AML‏
670 ‎‡a Author's BPR1K653, a novel Aurora kinase inhibitor, exhibits potent anti-proliferative activity in MDR1 (P-gp170)-mediated multidrug-resistant cancer cells‏
670 ‎‡a Author's Cloning, mapping, and characterization of the human sorbin and SH3 domain containing 1 (SORBS1) gene: a protein associated with c-Abl during insulin signaling in the hepatoma cell line Hep3B‏
670 ‎‡a Author's Discovery and evaluation of 3-phenyl-1H-5-pyrazolylamine-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).‏
670 ‎‡a Author's Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3‏
670 ‎‡a Author's Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).‏
670 ‎‡a Author's Molecular scanning of the human sorbin and SH3-domain-containing-1 (SORBS1) gene: positive association of the T228A polymorphism with obesity and type 2 diabetes‏
670 ‎‡a Author's SLC2A10 genetic polymorphism predicts development of peripheral arterial disease in patients with type 2 diabetes. SLC2A10 and PAD in type 2 diabetes‏
670 ‎‡a Author's Structural basis for the improved potency of peroxisome proliferator-activated receptor‏
670 ‎‡a Author's Structural basis for the improved potency of peroxisome proliferator-activated receptor (PPAR) agonists‏
670 ‎‡a Author's Structure-based drug design of novel Aurora kinase A inhibitors: structural basis for potency and specificity‏
670 ‎‡a Author's Suppression of Stat3 activity sensitizes gefitinib-resistant non small cell lung cancer cells‏
909 ‎‡a (orcid) 000000015023310x‏ ‎‡9 1‏
919 ‎‡a bpr1j097anovelflt3kinaseinhibitorexertspotentinhibitoryactivityagainstaml‏ ‎‡A BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AML‏ ‎‡9 1‏
919 ‎‡a bpr1k653anovelaurorakinaseinhibitorexhibitspotentantiproliferativeactivityinmdr1pgp170mediatedmultidrugresistantcancercells‏ ‎‡A BPR1K653, a novel Aurora kinase inhibitor, exhibits potent anti-proliferative activity in MDR1 (P-gp170)-mediated multidrug-resistant cancer cells‏ ‎‡9 1‏
919 ‎‡a cloningmappingandcharacterizationofthehumansorbinandsh3domaincontaining1sorbs1geneaproteinassociatedwith100ablduringinsulinsignalinginthehepatomacelllinehep3b‏ ‎‡A Cloning, mapping, and characterization of the human sorbin and SH3 domain containing 1 (SORBS1) gene: a protein associated with c-Abl during insulin signaling in the hepatoma cell line Hep3B‏ ‎‡9 1‏
919 ‎‡a discoveryandevaluationof3phenyl1h5pyrazolylaminebasedderivativesaspotentselectiveandefficaciousinhibitorsoffmsliketyrosinekinase3flt3‏ ‎‡A Discovery and evaluation of 3-phenyl-1H-5-pyrazolylamine-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).‏ ‎‡9 1‏
919 ‎‡a discoveryof3phenyl1h5pyrazolylaminederivativescontainingaureapharmacophoreaspotentandefficaciousinhibitorsoffmsliketyrosinekinase3‏ ‎‡A Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3‏ ‎‡9 1‏
919 ‎‡a discoveryof3phenyl1h5pyrazolylaminederivativescontainingaureapharmacophoreaspotentandefficaciousinhibitorsoffmsliketyrosinekinase3flt3‏ ‎‡A Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).‏ ‎‡9 1‏
919 ‎‡a molecularscanningofthehumansorbinandsh3domaincontaining1sorbs1genepositiveassociationofthet228apolymorphismwithobesityandtype2diabetes‏ ‎‡A Molecular scanning of the human sorbin and SH3-domain-containing-1 (SORBS1) gene: positive association of the T228A polymorphism with obesity and type 2 diabetes‏ ‎‡9 1‏
919 ‎‡a slc2a10geneticpolymorphismpredictsdevelopmentofperipheralarterialdiseaseinpatientswithtype2diabetesslc2a10andpadintype2diabetes‏ ‎‡A SLC2A10 genetic polymorphism predicts development of peripheral arterial disease in patients with type 2 diabetes. SLC2A10 and PAD in type 2 diabetes‏ ‎‡9 1‏
919 ‎‡a structuralbasisfortheimprovedpotencyofperoxisomeproliferatoractivatedreceptor‏ ‎‡A Structural basis for the improved potency of peroxisome proliferator-activated receptor‏ ‎‡9 1‏
919 ‎‡a structuralbasisfortheimprovedpotencyofperoxisomeproliferatoractivatedreceptorpparagonists‏ ‎‡A Structural basis for the improved potency of peroxisome proliferator-activated receptor (PPAR) agonists‏ ‎‡9 1‏
919 ‎‡a structurebaseddrugdesignofnovelaurorakinaseainhibitorsstructuralbasisforpotencyandspecificity‏ ‎‡A Structure-based drug design of novel Aurora kinase A inhibitors: structural basis for potency and specificity‏ ‎‡9 1‏
919 ‎‡a suppressionofstat3activitysensitizesgefitinibresistantnonsmallcelllungcancercells‏ ‎‡A Suppression of Stat3 activity sensitizes gefitinib-resistant non small cell lung cancer cells‏ ‎‡9 1‏
919 ‎‡a 3phenyl1h5pyrazolylaminebasedderivativesaspotentandefficaciousinhibitorsoffmsliketyrosinekinase3‏ ‎‡A 3-Phenyl-1H-5-pyrazolylamine-based derivatives as potent and efficacious inhibitors of FMS-like tyrosine kinase-3‏ ‎‡9 1‏
919 ‎‡a 3phenyl1h5pyrazolylaminebasedderivativesaspotentandefficaciousinhibitorsoffmsliketyrosinekinase3flt3‏ ‎‡A 3-Phenyl-1H-5-pyrazolylamine-based derivatives as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).‏ ‎‡9 1‏
919 ‎‡a 3dqsarassisteddrugdesignidentificationofapotentquinazolinebasedaurorakinaseinhibitor‏ ‎‡A 3D-QSAR-assisted drug design: identification of a potent quinazoline-based Aurora kinase inhibitor.‏ ‎‡9 1‏
919 ‎‡a cellbasedhighthroughputscreenforepidermalgrowthfactorreceptorpathwayinhibitors‏ ‎‡A A cell-based high-throughput screen for epidermal growth factor receptor pathway inhibitors‏ ‎‡9 1‏
919 ‎‡a novelauroraainhibitorbpr1k0609s1sensitizescolorectaltumorcellsto5fluorofracil5futreatment‏ ‎‡A A novel aurora-A inhibitor, BPR1K0609S1, sensitizes colorectal tumor cells to 5-fluorofracil (5-FU) treatment‏ ‎‡9 1‏
919 ‎‡a antiviraldrugdiscoveryagainstsarscov‏ ‎‡A Antiviral drug discovery against SARS-CoV.‏ ‎‡9 1‏
919 ‎‡a associationstudyofgeneticpolymorphismsofslc2a10geneandtype2diabetesinthetaiwanesepopulation‏ ‎‡A Association study of genetic polymorphisms of SLC2A10 gene and type 2 diabetes in the Taiwanese population.‏ ‎‡9 1‏
919 ‎‡a aurorakinaseainhibitorsidentificationsarexplorationandmolecularmodelingof67dihydro4hpyrazolopyrrolopyrimidine58dionescaffold‏ ‎‡A Aurora kinase A inhibitors: identification, SAR exploration and molecular modeling of 6,7-dihydro-4H-pyrazolo-[1,5-a]pyrrolo[3,4-d]pyrimidine-5,8-dione scaffold‏ ‎‡9 1‏
919 ‎‡a aurorakinaseinhibitorsrevealmechanismsofhurpinnucleationofcentrosomalandkinetochoremicrotubules‏ ‎‡A Aurora kinase inhibitors reveal mechanisms of HURP in nucleation of centrosomal and kinetochore microtubules‏ ‎‡9 1‏
996 ‎‡2 ISNI|0000000063422332‏
996 ‎‡2 LC|n 2018034607‏
996 ‎‡2 LC|n 78060885‏
996 ‎‡2 CYT|AC000251432‏
996 ‎‡2 CYT|AC000251431‏
996 ‎‡2 CYT|AC000252696‏
996 ‎‡2 CYT|AC000644430‏
996 ‎‡2 ISNI|0000000044785840‏
996 ‎‡2 ISNI|0000000064295144‏
996 ‎‡2 DNB|136900232‏
996 ‎‡2 CYT|AC000438554‏
996 ‎‡2 NII|DA07171442‏
996 ‎‡2 ISNI|0000000063827065‏
996 ‎‡2 CYT|AC000229691‏
996 ‎‡2 RERO|A019077825‏
996 ‎‡2 NII|DA18219697‏
996 ‎‡2 DNB|1032933194‏
996 ‎‡2 CYT|AC000251229‏
996 ‎‡2 CYT|AC000251222‏
996 ‎‡2 CYT|AC000251223‏
996 ‎‡2 CAOONL|ncf10991992‏
996 ‎‡2 CYT|AC000251226‏
996 ‎‡2 LC|nr 95007776‏
996 ‎‡2 LC|n 81061432‏
996 ‎‡2 LC|n 88193317‏
996 ‎‡2 ISNI|0000000026441868‏
996 ‎‡2 DNB|121332659‏
996 ‎‡2 SUDOC|133288633‏
996 ‎‡2 DNB|1028231148‏
996 ‎‡2 LC|no2012000765‏
996 ‎‡2 CYT|AC000252669‏
996 ‎‡2 CYT|AC000252666‏
996 ‎‡2 CYT|AC000614593‏
996 ‎‡2 NLA|000036709095‏
996 ‎‡2 CYT|AC000008115‏
996 ‎‡2 CYT|AC000545330‏
996 ‎‡2 LC|n 79150051‏
996 ‎‡2 CYT|AC000251018‏
996 ‎‡2 CYT|AC000251910‏
996 ‎‡2 CYT|AC000219279‏
996 ‎‡2 CYT|AC000639698‏
996 ‎‡2 CYT|AC000652952‏
996 ‎‡2 LC|no 94015030‏
996 ‎‡2 CYT|AC000219277‏
996 ‎‡2 ISNI|0000000063514755‏
996 ‎‡2 NLA|000036670732‏
996 ‎‡2 CYT|AC000002968‏
996 ‎‡2 LC|n 82020941‏
996 ‎‡2 ISNI|0000000425570931‏
996 ‎‡2 LC|n 78051798‏
996 ‎‡2 NII|DA02980861‏
996 ‎‡2 CYT|AC000252964‏
996 ‎‡2 CYT|AC000591752‏
996 ‎‡2 CYT|AC000591751‏
996 ‎‡2 LC|no2014050890‏
996 ‎‡2 ISNI|0000000027166781‏
996 ‎‡2 ISNI|0000000063414228‏
996 ‎‡2 CYT|AC000252968‏
996 ‎‡2 CYT|AC000219475‏
996 ‎‡2 CYT|AC000646953‏
996 ‎‡2 CYT|AC000219187‏
996 ‎‡2 ISNI|0000000064311220‏
996 ‎‡2 CYT|AC000616011‏
996 ‎‡2 NLA|000036688214‏
996 ‎‡2 CYT|AC000219189‏
996 ‎‡2 CYT|AC000219188‏
996 ‎‡2 CYT|AC000252182‏
996 ‎‡2 LC|n 82051132‏
996 ‎‡2 CYT|AC000504480‏
996 ‎‡2 LC|nr 96014182‏
996 ‎‡2 BNF|17936851‏
996 ‎‡2 SUDOC|256306443‏
996 ‎‡2 CYT|AC000636495‏
996 ‎‡2 NLA|000036641338‏
996 ‎‡2 LC|n 82033050‏
996 ‎‡2 CYT|AC000653888‏
996 ‎‡2 LC|no2017165142‏
996 ‎‡2 DNB|118980327‏
996 ‎‡2 DNB|1071420941‏
996 ‎‡2 ISNI|0000000057564561‏
996 ‎‡2 BNF|15600705‏
996 ‎‡2 NLA|000036729048‏
996 ‎‡2 CYT|AC000251461‏
996 ‎‡2 DNB|1019537388‏
996 ‎‡2 CYT|AC000644876‏
996 ‎‡2 CYT|AC000251466‏
996 ‎‡2 CYT|AC000250995‏
996 ‎‡2 CYT|AC000250994‏
996 ‎‡2 ISNI|000000006433852X‏
996 ‎‡2 CYT|AC000250991‏
996 ‎‡2 LC|n 86022939‏
996 ‎‡2 CYT|AC000632006‏
996 ‎‡2 CYT|AC000639396‏
996 ‎‡2 ISNI|0000000064308662‏
996 ‎‡2 LC|no2018157718‏
996 ‎‡2 CYT|AC000252271‏
996 ‎‡2 CYT|AC000631730‏
996 ‎‡2 ISNI|0000000064288067‏
996 ‎‡2 DNB|1195779763‏
996 ‎‡2 CYT|AC000252709‏
996 ‎‡2 CYT|AC000399397‏
996 ‎‡2 N6I|vtls001399409‏
996 ‎‡2 CYT|AC000646985‏
996 ‎‡2 LC|nr 99018388‏
996 ‎‡2 DNB|1230823328‏
996 ‎‡2 NLA|000036643906‏
996 ‎‡2 CYT|AC000251228‏
996 ‎‡2 ISNI|0000000063583849‏
996 ‎‡2 ISNI|0000000063743099‏
996 ‎‡2 NLA|000036633946‏
996 ‎‡2 LC|n 2015190853‏
996 ‎‡2 CYT|AC000251814‏
996 ‎‡2 CYT|AC000251817‏
996 ‎‡2 CYT|AC000251816‏
996 ‎‡2 LC|no 00033310‏
996 ‎‡2 CYT|AC000641286‏
996 ‎‡2 CYT|AC000252416‏
996 ‎‡2 LC|nr 92018085‏
996 ‎‡2 CYT|AC000641199‏
996 ‎‡2 ISNI|0000000063628381‏
996 ‎‡2 LC|n 78022837‏
996 ‎‡2 LC|nr 97044088‏
996 ‎‡2 CYT|AC000219428‏
996 ‎‡2 CYT|AC000219398‏
996 ‎‡2 CYT|AC000652615‏
996 ‎‡2 CYT|AC000219423‏
996 ‎‡2 CYT|AC000219397‏
996 ‎‡2 ISNI|0000000063321216‏
996 ‎‡2 ISNI|000000044459869X‏
996 ‎‡2 CYT|AC000219306‏
996 ‎‡2 ISNI|0000000063568462‏
996 ‎‡2 CYT|AC000251853‏
996 ‎‡2 NLA|000036605642‏
996 ‎‡2 LC|n 83138665‏
996 ‎‡2 CYT|AC000504028‏
996 ‎‡2 LC|n 84081836‏
996 ‎‡2 LC|nr 94014719‏
996 ‎‡2 CYT|AC000252552‏
996 ‎‡2 CYT|AC000219490‏
996 ‎‡2 CYT|AC000219492‏
996 ‎‡2 CYT|AC000219498‏
996 ‎‡2 CYT|AC000251325‏
996 ‎‡2 CYT|AC000252852‏
996 ‎‡2 CYT|AC000640962‏
996 ‎‡2 LC|nr 90029325‏
996 ‎‡2 ISNI|0000000063582117‏
996 ‎‡2 CYT|AC000253098‏
996 ‎‡2 NLA|000036609733‏
996 ‎‡2 LC|n 85013347‏
996 ‎‡2 CYT|AC000253257‏
996 ‎‡2 CYT|AC000253256‏
996 ‎‡2 NLA|000036698590‏
996 ‎‡2 NLA|000036620186‏
996 ‎‡2 LC|n 88246063‏
996 ‎‡2 CYT|AC000251781‏
996 ‎‡2 J9U|987007603776105171‏
996 ‎‡2 CYT|AC000238273‏
996 ‎‡2 LNB|LNC10-000050237‏
996 ‎‡2 DNB|1317527127‏
996 ‎‡2 LC|nr 94036407‏
996 ‎‡2 ISNI|0000000444639527‏
996 ‎‡2 CYT|AC000644420‏
996 ‎‡2 ISNI|0000000063587743‏
996 ‎‡2 NLA|000036713953‏
996 ‎‡2 NLA|000036665416‏
996 ‎‡2 ISNI|0000000497669455‏
996 ‎‡2 LC|n 85296182‏
996 ‎‡2 ISNI|0000000083295692‏
996 ‎‡2 CAOONL|ncf10025919‏
996 ‎‡2 DNB|1127177494‏
996 ‎‡2 CYT|AC000251253‏
996 ‎‡2 CYT|AC000251250‏
996 ‎‡2 CYT|AC000503885‏
996 ‎‡2 ISNI|0000000063271482‏
996 ‎‡2 ISNI|0000000055553148‏
996 ‎‡2 LC|n 97062595‏
996 ‎‡2 NLA|000036719067‏
996 ‎‡2 CYT|AC000639297‏
996 ‎‡2 LC|nr 93011026‏
996 ‎‡2 CYT|AC000643708‏
996 ‎‡2 CYT|AC000252776‏
996 ‎‡2 LIH|LNB:V-301218;=BB‏
996 ‎‡2 SUDOC|171196791‏
996 ‎‡2 DNB|1315915677‏
996 ‎‡2 DNB|1136666036‏
996 ‎‡2 LC|nr 94042634‏
996 ‎‡2 CYT|AC000219260‏
996 ‎‡2 CYT|AC000219399‏
996 ‎‡2 CYT|AC000219266‏
996 ‎‡2 NLA|000036602504‏
996 ‎‡2 CYT|AC000252269‏
996 ‎‡2 CYT|AC000643364‏
996 ‎‡2 CYT|AC000634640‏
996 ‎‡2 BNF|15104639‏
996 ‎‡2 CYT|AC000251675‏
996 ‎‡2 CYT|AC000219464‏
996 ‎‡2 CYT|AC000219467‏
996 ‎‡2 CYT|AC000219460‏
996 ‎‡2 CYT|AC000219461‏
996 ‎‡2 CYT|AC000219462‏
996 ‎‡2 CYT|AC000219463‏
996 ‎‡2 NLA|000036730380‏
996 ‎‡2 CYT|AC000219469‏
996 ‎‡2 NII|DA03277135‏
996 ‎‡2 CYT|AC000252587‏
996 ‎‡2 CYT|AC000219192‏
996 ‎‡2 CYT|AC000219395‏
996 ‎‡2 CYT|AC000252824‏
996 ‎‡2 CAOONL|ncf10426204‏
996 ‎‡2 CYT|AC000252529‏
996 ‎‡2 CYT|AC000251076‏
996 ‎‡2 NLA|000036605096‏
996 ‎‡2 DNB|1136726853‏
996 ‎‡2 CYT|AC000250948‏
996 ‎‡2 CYT|AC000253164‏
996 ‎‡2 ISNI|0000000056159943‏
996 ‎‡2 CYT|AC000253205‏
996 ‎‡2 CYT|AC000251151‏
996 ‎‡2 ISNI|000000004747209X‏
996 ‎‡2 NII|DA13496022‏
996 ‎‡2 CYT|AC000641032‏
996 ‎‡2 CYT|AC000654953‏
996 ‎‡2 ISNI|0000000064349181‏
996 ‎‡2 CYT|AC000644869‏
996 ‎‡2 DNB|1241343527‏
996 ‎‡2 CYT|AC000251103‏
996 ‎‡2 LC|n 89116722‏
996 ‎‡2 CYT|AC000644865‏
996 ‎‡2 CYT|AC000251298‏
996 ‎‡2 DNB|1146605641‏
996 ‎‡2 J9U|987007352744105171‏
996 ‎‡2 CYT|AC000590618‏
996 ‎‡2 LC|no 00044020‏
996 ‎‡2 CYT|AC000644463‏
996 ‎‡2 CYT|AC000644461‏
996 ‎‡2 CYT|AC000663623‏
996 ‎‡2 CYT|AC000590617‏
996 ‎‡2 LC|n 85268810‏
996 ‎‡2 CYT|AC000251896‏
996 ‎‡2 LC|no2020067053‏
996 ‎‡2 ISNI|0000000064261999‏
996 ‎‡2 DNB|1179200993‏
996 ‎‡2 CYT|AC000658426‏
996 ‎‡2 ISNI|0000000064129656‏
996 ‎‡2 ISNI|000000006349511X‏
996 ‎‡2 CYT|AC000504024‏
996 ‎‡2 ISNI|0000000064051692‏
996 ‎‡2 CYT|AC000634424‏
996 ‎‡2 LC|nr 96007874‏
996 ‎‡2 CYT|AC000252605‏
997 ‎‡a 0 0 lived 0 0‏ ‎‡9 1‏